Skip to Content

Pegloticase

In the US, Pegloticase (pegloticase systemic) is a member of the drug class antihyperuricemic agents and is used to treat Gout.

US matches:

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

M04AX02

CAS registry number (Chemical Abstracts Service)

0885051-90-1

Chemical Formula

C6196-H9720-N1632-O1792-S32

Therapeutic Categories

Enzyme

Treatment of gout

Chemical Name

Tetramer α₄ of des-(1-5)-[6-threonine, 45-threonine, 290-lysine, 300-serine]uricase (EC 1.7.3.3, urate oxidase) from Sus scrofa(porcine), non acetylated, of which some of the lysine 6-amine residues are engaged in a carbamate linkage with a monomethylic e (WHO )

Foreign Names

  • Pegloticasum (Latin)
  • Pegloticase (German)
  • Pégloticase (French)
  • Pegloticasa (Spanish)

Generic Names

  • Pegloticase (OS: USAN)
  • Methoxypolyethylene glycol uricase (IS)
  • PEG-Urat oxidase (IS)
  • PEG-Uricase (IS)

Brand Names

  • Krystexxa
    Crealta, Poland; Crealta, United States; Savient, Spain

International Drug Name Search

Glossary

TermDefinition
ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Hide